GDF-9 promotes the growth of prostate cancer cells by protecting them from apoptosis

Journal of Cellular Physiology

Volumn 225, Issue 2, 2010, Pages 529-536

  Bokobza, Sivan M ^a   Ye, Lin ^a   Kynaston, Howard G ^a   Jiang, Wen G ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CASPASE 3; GROWTH DIFFERENTIATION FACTOR 9; RIBOZYME; BIOLOGICAL MARKER; RECOMBINANT PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL GROWTH; CONTROLLED STUDY; FLOW CYTOMETRY; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TRANSGENE; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS; TIME; TUMOR CELL LINE;

MAMMALIA;

APOPTOSIS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH DIFFERENTIATION FACTOR 9; HUMANS; MALE; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 77956537718     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22235     Document Type: Article

References (23)

1. Aaltonen J, Laitinen MP, Vuojolainen K, Jaatinen R, Horelli-Kuitunen N, Seppa L, Louhio H, Tuuri T, Sjoberg J, Butzow R, Hovata O, Dale L, Ritvos O. 1999. Human growth differentiation factor 9 (GDF-9) and its novel homolog GDF-9B are expressed in oocytes during early folliculogenesis. J Clin Endocrinol Metab 84:2744-2750.
2. Bobinac D, Maric I, Zoricic S, Spanjol J, Dordevic G, Mustac E, Fuckar Z. 2005. Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer. Croat Med J 46:389-396. (Pubitemid 40686482)
3. Brubaker KD, Corey E, Brown LG, Vessella RL. 2004. Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 91:151-160.
4. Chen D, Zhao M, Mundy GR. 2004. Bone morphogenetic proteins. Growth Factors 22:233-241.
5. Coleman RE. 2006. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s-6249s.
6. Davies SR, Watkins G, Douglas-Jones A, Mansel RE, Jiang WG. 2008. Bone morphogenetic proteins 1 to 7 in human breast cancer, expression pattern and clinical/prognostic relevance. J Exp Ther Oncol 7:327-338.
7. Hanavadi S, Martin TA, Watkins G, Mansel RE, Jiang WG. 2007. The role of growth differentiation factor-9 (GDF-9) and its analog, GDF-9b/BMP-15, in human breast cancer. Ann Surg Oncol 14:2159-2166. (Pubitemid 46988265)
8. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. 2009. Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
9. Koli KM, Arteaga CL. 1997. Predominant cytosolic localization of type II transforming growth factor beta receptors in human breast carcinoma cells. Cancer Res 57:970-977. (Pubitemid 27098026)
10. Mazerbourg S, Klein C, Roh J, Kaivo-Oja O, Mottershead DG, Korchynskyi O, Ritvos O, Hsueh AJ. 2004. Growth differentiation factor-9 signaling is mediated by the type I receptor, activin receptor-like kinase 5. Mol Endocrinol 18:653-665. (Pubitemid 38328209)
11. Nohe A, Hassel S, Ehrlich M, Neubauer F, Sebald W, Henis YI, Knaus P. 2002. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 277:5330-5338. (Pubitemid 34968578)
12. Nohe A, Keating E, Knaus P, Petersen NO. 2004. Signal transduction of bone morphogenetic protein receptors. Cell Signal 16:291-299.
13. Orisaka M, Orisaka S, Jiang JY, Craig J, Wang Y, Kotsuji F, Tsang BK. 2006. Growth differentiation factor 9 is antiapoptotic during follicular development from preantral to early antral stage. Mol Endocrinol 20:2456-2468. (Pubitemid 44496414)
14. Shi Y, Massague J. 2003. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685-700. (Pubitemid 36724933)
15. Sims NA, Gooi JH. 2008. Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol 19:444-451.
16. Slee EA, Adrain C, Martin SJ. 2001. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 276:7320-7326.
17. Su YQ, Sugiura K, Wigglesworth K, O'Brien MJ, Affourtit JP, Pangas SA, Matzuk MM, Eppig JJ. 2008. Oocyte regulation of metabolic cooperativity between mouse cumulus cells and oocytes: BMP15 and GDF9 control cholesterol biosynthesis in cumulus cells. Development 135:111-121. (Pubitemid 351201485)
18. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. 2002. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62:1832-1837. (Pubitemid 34408510)
19. Vitt UA, Hayashi M, Klein C, Hsueh AJ. 2000. Growth differentiation factor-9 stimulates proliferation but suppresses the follicle-stimulating hormone-induced differentiation of cultured granulosa cells from small antral and preovulatory rat follicles. Biol Reprod 62:370-377. (Pubitemid 30067338)
20. Ye L, Lewis-Russell JM, Kynaston H, Jiang WG. 2007. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists. J Urol 178:1086-1091. (Pubitemid 47211048)
21. Ye L, Kynaston H, Jiang WG. 2008. Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol Cancer Res 6:1594-1606.
22. Ye L, Kynaston H, Jiang WG. 2009. Bone morphogenetic protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway. J Urol 181:2749-2759.
23. Zhuang Z, Jian P, Longjiang L, Bo H, Wenlin X. 2009. Oral cancer cells with different potential of lymphatic metastasis displayed distinct biologic behaviors and gene expression profiles. J Oral Pathol Med 39:168-175.